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AMIODARONE IS an antiarrhythmic that commonly is
indicated in the cardiothoracic surgical intensive care unit for
the management of atrial fibrillation.1,2 Acute lung injury associated with amiodarone exposure is a rare but life-threatening
syndrome that may complicate perioperative management.3
This case conference presents a complex clinical scenario that
included acute pulmonary toxicity in the setting of amiodarone
therapy for atrial fibrillation. The subsequent expert commentaries explore the diagnostic and management options for this
pharmacologic complication in light of the recent literature.
The project was supported by institutional funding.
1
Address correspondence to John G.T. Augoustides, MD, FASE, FAHA,
Cardiovascular and Thoracic Section, Anesthesiology and Critical Care,
Dulles 680, HUP, 3400 Spruce St, Philadelphia, PA, 19104-4283.
E-mail address: yiandoc@hotmail.com (J.G. Augoustides).

Case Presentation
An 89-year-old woman with severe, symptomatic aortic stenosis presented to the authors’ institution for a transcatheter aortic
valve replacement via a percutaneous femoral approach. The
patient had multiple comorbidities including mild diastolic dysfunction, paroxysmal atrial fibrillation stabilized with sotalol therapy, and sick sinus syndrome that had required a dual-chamber
pacemaker. The aortic valve replacement was complicated intraoperatively by an injury to the vertebral artery that required clinical
rescue with emergent tracheal intubation, mechanical ventilation,
massive transfusion, titrated vasopressor therapy, and endovascular stenting for repair of the vertebral artery.
The patient was admitted to the cardiothoracic surgery
intensive care unit for further management. Her postoperative
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Fig 1. Progression of acute lung injury by chest radiograph. Panel A: Preoperative chest radiograph serves as a clinical baseline. Panel B: Chest radiograph on the
10th postoperative day revealed new diffuse alveolar infiltrates occurring within 24 hours of amiodarone. Panel C: Chest radiograph on the 12th postoperative day
has documented progression of the acute lung injury pattern.

course in the first week was complicated by paroxysmal atrial
fibrillation requiring electrical cardioversion and titrated sotalol therapy. Furthermore, she was diagnosed with ventilatorassociated pneumonia that resolved with aggressive antibiotic
therapy. The sotalol therapy was discontinued due to associated hypotension. Her trial of tracheal intubation was unsuccessful due to vocal cord dysfunction. In the second week, she
underwent successful percutaneous tracheostomy. She was
challenged with amiodarone for control of ongoing paroxysmal atrial fibrillation.
Her radiographic imaging series subsequently developed
diffuse ground-glass opacities that were concerning for acute
lung injury (refer to Fig 1). Although her infectious workup
including bronchoscopy with bronchoalveolar lavage was negative at this juncture, her antibiotic therapy was broadened
empirically for an extended course. A chest computed tomography scan was obtained on the 12th postoperative day to evaluate the full extent of the alveolar process that was apparent
on chest radiograph. This detailed cross-sectional imaging
revealed diffuse alveolar infiltrates with areas of consolidation
throughout the lung fields (refer to Fig 2).
Given these findings on detailed chest imaging and the
recent exposure to amiodarone, the diagnosis of acute amiodarone pulmonary toxicity was entertained. The amiodarone
was discontinued promptly and an empirical course of steroids
was commenced. Her subsequent clinical course improved
gradually, her chest radiograph cleared, and she was removed
from the ventilator. She ultimately was discharged from the
intensive care unit on the 37th postoperative day and after further recovery was transferred to a skilled nursing facility in
fair condition.

Case Discussion
Amiodarone is a benzofuran derivative with potent class III
antiarrhythmic activity.1-3 The medication was developed and
marketed in the 1960s as a coronary dilator and antianginal
medication. In the 1970s, amiodarone was discovered to have
antiarrhythmic properties and its popularity as an effective
antiarrhythmic rapidly became established.3,4 This enthusiasm

was dampened subsequently by the emergence of clinical toxicity, including to the eye, thyroid, lung, and liver.3-8
Despite the side-effect profile, amiodarone has regained
popularity for rhythm control after cardiothoracic procedures
due to its efficacy and hemodynamic tolerance in this setting.1-3 Furthermore, its toxic effects are uncommon in the
postoperative period due to the short-term exposure that
typically is required.1-8 The pharmacokinetics and pharmacodynamics of amiodarone, as well as its clinical applications, already have been reviewed in the Journal.3,9 The
further discussion is focused on the pulmonary toxicity
associated with amiodarone.
The spectrum of amiodarone-induced pulmonary toxicity
can vary in clinical presentation and time course, including
acute, subacute, and chronic syndromes.3-10 The clinical phenotype for this complication includes diffuse alveolar hemorrhage, acute respiratory distress syndrome (ARDS), and
diffuse interstitial pneumonitis.10,11 The acute presentation of
ARDS may occur in the postoperative period, as illustrated in
this case conference.3 The diagnosis of this entity is challenging, because clinicians primarily must rely on clinical suspicion with a paucity of reliable tests to suggest the diagnosis.
The pattern of acute lung injury on cross-sectional imaging
often can be an important diagnostic clue.12
Adult cardiac surgical patients often experience a pronounced systemic inflammatory response due to factors such
as the operative stress response and infection. The clinical
diagnosis of amiodarone as a possible cause for diffuse alveolar injury is suggested in the setting of amiodarone exposure
without any other overt etiology.3,12 Cross-sectional imaging
in drug-induced alveolar injury typically will reveal a diffuse
alveolar pattern throughout the lung fields; whereas the alveolar injury pattern in infectious etiologies often is concentrated
in the gravity-dependent lung regions such as the bases (refer
to Fig 2).3,13
Bronchoscopy with alveolar lavage in patients with amiodarone-induced pulmonary toxicity may reveal macrophages
with foamy cytoplasm.11,13 Although this histologic finding is
sensitive for acute lung injury due to amiodarone, it also is
found in other pulmonary diseases and is not specific for amiodarone-induced lung toxicity. The presence of foamy
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Fig 2. Progression of acute lung injury by serial computed tomography (CT) scans. Panel A: Preoperative chest CT scan serves as a clinical baseline. Panels B-D:
Chest CT scan on the 12th postoperative day shows the lung fields in a cross-sectional fashion. There are extensive alveolar infiltrates with areas of consolidation
throughout the lung fields.

macrophages in patients exposed to amiodarone is postulated
to be due to the creation of oxygen free radicals and increase
of phospholipids in lung tissue secondary to the cytotoxic
effects of amiodarone.12,14,15 Clinical trials have suggested the
diagnostic role of measuring glycoproteins released into the
alveoli and serum by type II pneumocytes in acute alveolar
injury.16-18 Although these markers may be elevated in amiodarone toxicity, their role has remained limited due to their
presence in many forms of alveolar injury and so they are not
specific for amiodarone-induced lung injury.
The literature regarding the pathogenesis and presentation
of acute lung injury due to amiodarone is limited, and, thus,
there are still major gaps in the evidence.3 This literature is
confounded by variations in definitions, dosing schedules,
drug formulations, routes of administration, and duration of
therapy, and has been reviewed recently in the Journal.3,19
The diagnosis and management of the subacute and chronic
presentations may not necessarily dictate the clinical approach
to acute pulmonary toxicity from amiodarone.3
The mainstay of therapy for acute lung injury from amiodarone is immediate cessation of this drug.3,19 Although there is
limited consensus, empirical steroid therapy may be indicated
to dampen the acute inflammatory response and to encourage
clinical resolution. The clinical guidance for dose and duration
of this steroid therapy remains to be determined. The duration
of amiodarone-induced acute lung injury is variable. There
may be prompt resolution or recovery can be extended due to
the long half-life of amiodarone and its propensity to concentrate in lung tissue, especially in type II pneumocytes.19-21 In one particular patient, it took 60 days after
amiodarone cessation for pulmonary infiltrates to clear with
full clinical resolution and a good clinical outcome.20
These considerations are important to consider when advising the patient and family about the expected clinical
course and goals of care.

In summary, amiodarone remains a popular and effective
choice for pharmacologic control of arrhythmias in adult cardiac surgical patients. Although rare, the risk of acute lung
injury must be considered in this setting, especially in patients
who manifest new lung infiltrates with no overt etiology. The
care team should continue to use amiodarone as indicated but
must be aware that acute lung injury is a rare and serious
adverse drug reaction.
Expert Commentary (Dr. Saluja/Dr. Sanders)
This case conference highlights a rare side effect of amiodarone in the postoperative period. Briefly, an 89-year-old
woman with severe, symptomatic stenosis presented for transcatheter aortic valve replacement that was complicated by vertebral artery injury requiring massive transfusion, tracheal
intubation, and a trial of mechanical ventilation. The patient
required cardioversion and subsequent amiodarone dosing
because of repeated episodes of atrial fibrillation. Thereafter,
she developed an acute alveolar pattern of lung injury days
after amiodarone therapy was initiated. Once the amiodarone
was stopped and steroids were administered, the patient’s condition improved.
Amiodarone, a class III antiarrhythmic drug that blocks
voltage-gated potassium channels, first was used as an antianginal medication, and then as an effective therapy for various
ventricular and supraventricular tachyarrhythmias.22-25 Furthermore, amiodarone frequently is administered for perioperative prophylaxis for atrial arrhythmias.3,26 The drug can
maintain a sinus rhythm in patients with paroxysmal atrial
fibrillation and potentially can assist in conversion of atrial
fibrillation to a sinus rhythm.1-3;22-25
In the presented case, the patient developed intermittent
atrial fibrillation with rapid ventricular response. Therefore, an
intravenous load of amiodarone was administered followed by
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ongoing oral loading. The perioperative literature has suggested that there is no clear correlation between acute amiodarone therapy at recommended levels and the development of
acute lung injury.3 In the outpatient setting, lower-dosage regimens may be associated with a reduced risk of amiodaroneinduced pulmonary toxicity.10,27,29-31 Over the years, tailored
doses of amiodarone have been selected to minimize the risk
of lung toxicity, although there is no safe dose.20,31-35 Indeed,
toxicity has been reported at commonly prescribed maintenance dosages of amiodarone, even at ultra-low exposure levels.20,34-36 Therefore, in this patient, it is likely that pulmonary
injury still would have developed, signifying the complicated
nature of her hospital course.
The pathogenesis of amiodarone lung toxicity also has been
linked to supplementary oxygen, especially when the concentration is high.30,37,38 Notably, the risk may be potentiated
whether the exposure is to isolated oxygen or to oxygen combined with mechanical ventilation.20,36 In the presented case,
the patient received, at times, higher oxygen concentrations
that were indicated clinically in the perioperative period. Furthermore, amiodarone itself may induce production of oxygen
radicals, which are toxic and can cause cellular damage.30,31
The evidence linking oxygen concentration as an etiologic factor in this acute setting is limited and far from conclusive.3
Multiple mechanisms have been proposed to explain the
pathogenesis of amiodarone lung, including the impairment of
lipid metabolism leading to increased cellular phospholipid
content.20,28,29 This phospholipid accumulation results in
endothelium damage. Additionally, production of oxygen radicals may lead to direct damage of alveolar cell membranes,
eventually resulting in acute alveolar injury. 20,28,29 However,
because the etiology and pathogenesis still are being investigated, perhaps this diagnosis is one of exclusion with a high
index of clinical suspicion.3 Ultimately, the diagnosis was
cemented in this patient after clinical improvement followed
the cessation of amiodarone and a steroid trial.
In amiodarone-induced pulmonary toxicity, the lung parenchyma often is remarkable for ground-glass opacities, which
often are peripheral in location and may be found early.39 Furthermore, alveolar and/or interstitial infiltrates often are
apparent in both lung fields.39,40 In this case, the patient’s clinical course had failed to improve in the second postoperative
week, prompting consideration of a wide differential diagnosis. Subsequent detailed cross-sectional chest imaging showed
diffuse alveolar infiltrates with consolidation and ground-glass
opacities throughout both lung fields (refer to Fig 2). Overall,
high-resolution scanning with computed tomography can
reveal the extent of a pulmonary disease process to a greater
extent than plain chest radiography (refer to Fig. 1 and 2).39-42
This detailed chest imaging, coupled with appropriate clinical
suspicion, suggested the diagnosis in this patient.
The histology of amiodarone lung often will include injured
alveoli with lipid-laden foamy macrophages.41,42 The thorough
workup in this patient included bronchoscopy with titrated
lavage. Although these histologic findings are suggestive of
amiodarone-induced alveolar injury, they are not specific to
this disease process.43 Therefore, the presence of foamy
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macrophages can suggest the diagnosis, but does not definitively make the diagnosis. A high index of clinical suspicion,
combined with the appropriate clinical setting and chest imaging, are more important in the diagnostic process for amiodarone-induced pulmonary toxicity.3
Furthermore, a search for possible serum markers has been
ongoing. Select glycoproteins secreted by type II alveolar
pneumocytes have been evaluated as possible biomarkers for
pneumonitis.16-18 Because proliferation of type II pneumocytes
has been observed during the pathogenesis of amiodarone
lung, this approach may yield promising serum markers for
this pathologic process.44 But although this type of biomarker
has been shown to be elevated significantly in alveolitis, it
remains at this juncture a nonspecific marker for amiodaroneinduced lung injury.16-18, 44
The diagnosis of amiodarone lung requires a high clinical
suspicion and ultimately is a diagnosis of exclusion, as illustrated in this patient.45,46 Therefore, once this diagnosis has
been established, amiodarone administration immediately
should be ceased.45-47 Furthermore, although steroids commonly are prescribed in this setting, there is no general agreement on what the prescribed dose should be, and there appears
to be some variance as to the correct dosing regimen.3,45-47
However, it is reasonable to consider a steroid trial when substantial involvement of the lung parenchyma is apparent in
chest imaging.45-47
There is variability in the resolution phase of acute lung
injury associated with amiodarone therapy. The resolution
may be substantial but gradual, as in this patient. The patient
eventually was weaned from the ventilator and discharged
from the hospital. Therapy varies by patient, as each patient
responds differently to treatment. Furthermore, the concentration of amiodarone present in the lung tissue varies from
patient to patient, and this likely affects the duration of
required treatment.44-46 The steroid trial also can be titrated
according to the clinical trajectory.
There are several concluding comments to be made from
this excellent case presentation. The rare diagnosis of amiodarone-induced pulmonary toxicity should be considered whenever therapy is initiated. If atrial fibrillation is identified,
alternative medications should be considered. If amiodarone
use is deemed most appropriate, the lowest effective dose
should be considered. The oxygen concentration should be
minimized whenever clinically possible. Detailed cross-sectional chest imaging plays an important diagnostic role in this
setting. Clinical suspicion of this diagnosis should lead to cessation of amiodarone therapy, followed by steroid therapy.
Finally, the clinical trajectory also can be affected by serial
chest imaging.
Expert Commentary (Dr. Marchant/Dr. Fernando)
Amiodarone is one of the most common medications for
arrhythmias.4-8 Although it has many potential benefits, it is
accompanied by a host of possible side effects, including
amiodarone pulmonary toxicity.22-24, 33-35 In this case conference, the authors discuss an uncommon but very serious
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scenario, wherein a patient being treated with amiodarone for
unstable atrial fibrillation developed ARDS. Ultimately, this
conferred significant morbidity and contributed to a prolonged
hospitalization.
The association of amiodarone and pulmonary toxicity is
not new, and has an incidence in the range of 1%-to-10% in
prior studies, depending on variables such as definitions and
clinical setting.48 Older patients and those with prior pulmonary disease may be at elevated risk.49 Further possible risk
factors include male sex, delivery of high oxygen levels, and
previous cardiac or thoracic surgery.10,28-31,49 The daily and
cumulative treatment doses, as well as treatment duration, also
may play a role.20,32-38 Unfortunately, the clinical efforts to
minimize the risks of this lung toxicity have been limited due
to its ongoing prevalence despite smaller doses of amiodarone,
shorter durations of treatment, and even after discontinuation
of the drug.10,20,28-36
Classically, a patient would develop subacute interstitial
pneumonitis after being treated with amiodarone over a long
period.3 Symptoms often are nonspecific, such as cough and
shortness of breath. Infiltrates may be present bilaterally on
chest radiography.39,40 Computed tomography further highlights the extensive nature of the disease process, and pulmonary function tests demonstrate a restrictive defect, with a low
diffusing capacity of the lung for carbon monoxide.10,28-31,30,40
In contrast to this classic presentation, an acute lung injury
also has been described in association with amiodarone therapy.3 The clinical spectrum includes diffuse interstitial pneumonitis, diffuse interstitial hemorrhage, and acute respiratory
distress syndrome with diffuse alveolar injury.3 Clinical retrospective trials in the 1990s documented an incidence as high
as 10% of acute lung injury with the use of amiodarone therapy in the perioperative setting.50,51 Subsequent randomized
clinical trials with amiodarone have documented a very low
incidence, below 1%.3,52,53 Overall, these conflicting results
have suggested to some investigators that the extent to which
amiodarone is associated with acute lung injury may be limited, perhaps playing a role in a vulnerable patient, rather than
solely being the cause.3
The relationship between acute pulmonary toxicity and cardiothoracic surgery is particularly concerning because atrial
fibrillation is a common occurrence in the postoperative
period.1,2,5,6,54,55 To guide management of perioperative atrial
fibrillation in this setting, the Society of Cardiac Anesthesiologists and European Association of Cardiothoracic Anesthetists
recently have developed and published a practice advisory.9
Amiodarone therapy has been given a class IIa recommendation for the prevention of atrial fibrillation in patients in sinus
rhythm and at high risk for this arrhythmia. Furthermore, in
this practice advisory, amiodarone therapy was designated a
class IIa recommendation for rhythm control in episodes of
atrial fibrillation. Interestingly, although greater than 90% of
members from these two professional societies indicated that
they routinely chose amiodarone to treat atrial fibrillation,
only 30%-to-40% of members routinely chose it for prophylaxis.9 When queried further, the respondents indicated that
the adverse effects of amiodarone posed a significant barrier

for routine prophylaxis against perioperative atrial fibrillation.9
Although the authors of the practice advisory acknowledged
the possibility of acute lung injury with amiodarone, they reaffirmed that this typically results after longer exposure. This
likely explains, in part, the recommendations for amiodarone
in both the treatment and prophylaxis of perioperative atrial
fibrillation in the cardiothoracic setting. Although its incidence
may be lower in transcatheter compared to surgical aortic
valve replacement, many patients such as the one presented in
this case conference may present for transcatheter aortic valve
replacement with a prior history of atrial fibrillation.56,57 Also,
the approach may play a role, with transapical procedures possibly conferring more risk than transfemoral.56,57
ARDS is characterized by an immune-mediated damage to
alveolar endothelium with subsequent impairment in gas
exchange and pulmonary compliance.58,59 Although in the
overall population there are many risk factors, factors such
pneumonia, aspiration, sepsis, hemorrhagic shock, and blood
transfusion deserve mention as they specifically related to this
patient. Although there is conflicting evidence as to risk factors
specific to the cardiac surgical population, factors such as prior
cardiac surgery, complex procedures, emergency procedures,
and transfusion of more than three units of packed red blood
cells often are identified.59,60 Regardless of etiology, this syndrome is a major driver behind postoperative respiratory failure after cardiothoracic procedures. Unfortunately, when it
develops, it has been associated with a mortality rate as high
as 40%-to-80%.59,60
The patient presented in this case conference clearly had a
complex perioperative course with significant pulmonary
involvement. She required emergent tracheal intubation intraoperatively, with titrated mechanical ventilation and periods of
high concentrations of inspired oxygen. Her worsening respiratory status resulted in antibiotic therapy for presumed pneumonia, and intermittent bronchoscopy for pulmonary hygiene
and respiratory culture. When radiographic evidence was suggestive of diffuse alveolar injury, a differential diagnosis was
considered, with the ultimate diagnosis being amiodaroneinduced pulmonary toxicity with an ARDS as its phenotypic
manifestation. Because this diagnosis is uncommon and relies
on exclusion of more common etiologies, the care team was
appropriate in considering a robust differential diagnosis.
The response in the first postoperative week was clinically
consistent with ventilator-associated pneumonia that typically
develops about 48-to-72 hours after intubation.61 Although
this chest infection may occur in up to 25% of mechanically
ventilated patients, the risk is highest during the first five days
of endotracheal intubation.61 Indeed, this was addressed by the
critical care team as evidenced by the initiation of levofloxacin. The emergent nature of endotracheal intubation also opens
up the possibility of pulmonary aspiration. In emergency medicine, witnessed aspiration during endotracheal intubation has
an incidence of approximately 5%, whereas occult aspiration
(as assessed by pepsin analysis in tracheal aspirates) may occur
in up to 50% of emergent endotracheal intubations.62 Although
there certainly are differences between urgent perioperative
and emergency department intubations, especially regarding
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fasting status, this nevertheless does raise concern for the risk
of aspiration, particularly in patients requiring bag mask ventilation. Overall, these two aspects of the case are important
because a recent review noted that among all established risk
factors for ARDS, the preponderance of occurrence (upward
of 85%) can be attributed to pneumonia, aspiration, and
sepsis.63
The possibility of transfusion-associated acute lung injury
also was considered as a potential culprit for the patient’s
respiratory compromise.64 This form of alveolar injury has
been defined as new acute-onset lung injury with radiographic
evidence of bilateral infiltrates that occurs within six hours of
administration of blood products in a patient without other risk
factors for acute lung injury.64 Sometimes this syndrome may
follow exposure to just one unit of blood.64 These criteria have
come into question recently as critically ill patients, who have
additional risk factors for acute lung injury, also seem to sustain lung injuries with blood transfusions, albeit on a different
timeline.65,66 A recent cohort study of critically ill patients
found that the odds ratio for developing ARDS after blood
transfusion was 2.74 compared to controls who did not receive
blood.65 In light of this type of data, leaders have proposed a
delayed syndrome to describe lung injury manifesting after
blood transfusion over an extended timeline (six-72 hours after
transfusion) and independent of additional risk factors.65,66
This delayed acute lung injury occurred in up to a quarter of
transfused critically ill patients in a dose-dependent manner,
with additional units of blood increasing risk.66 Notably,
although this type of delayed acute lung injury is certainly a
consideration, this patient also experienced hemorrhagic shock
and massive blood transfusion, which are both independent
risk factors for ARDS, though whether this is a separate mechanism remains unclear.59,60,63-66
As outlined in this case conference, this patient had multiple etiologies to explain the development of ARDS. However,
the timeline did not strongly support some of these factors. In
fact, after exposure to these insults, the patient’s respiratory
status improved substantially to the point that she had a brief
trial of tracheal extubation, with her failure in this setting
being attributed to vocal cord dysfunction. The onset of the
diffuse alveolar injury after resolution of known instigators
makes the diagnosis of amiodarone lung all the more likely.
However, perhaps amiodarone is only partially to blame. A
recent comprehensive narrative review of this topic in the
Journal has questioned its prevalence, and highlighted the
scant recent literature, but did point out that amiodarone may
play a contributory role in the pathogenesis of postoperative
ARDS.3
Regardless of the postulated mechanisms, exposure to highoxygen concentrations, as well as cardiothoracic procedures,
seem to be risk factors for the development of amiodaroneinduced lung injury.10,28-31 These multiple associations suggest that this type of lung injury does not exist in a vacuum;
rather, its development occurs in already stressed lungs.36-38
Indeed, theories surrounding its pathogenesis involve a twostage phenomenon, with the first stage being a perioperative
stressor damaging the lungs enough for the second stage of
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amiodarone toxicity to result in ARDS.3 Could this have been
what happened in this patient? Perhaps this patient sustained
an initial lung injury that did not progress until exposed to the
added insult of amiodarone. On the other hand, did her initial
recovery suggest that amiodarone alone was the culprit?
Regardless, this case serves to raise awareness about the potential serious complications of this widely used medication.
In summary, although pulmonary toxicity classically is a
consequence of long-term amiodarone therapy, this case conference raises suspicion for the possibility of acute toxicity as
well. Unfortunately, the exact nature of the relationship
between amiodarone and acute alveolar injury is not
completely clear in the literature due to mixed findings. Until
additional evidence is available, recent clinical guidelines
have recommended amiodarone for the treatment and prophylaxis of atrial fibrillation complicating cardiac surgery. Nevertheless, despite the potential for acute lung injury, amiodarone
should be kept in mind, particularly when respiratory failure
persists and the etiology remains elusive despite comprehensive clinical investigation.
Conflict of Interest
None.
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